Bioinformatic modelling of SARS-CoV-2 pandemic with a focus on country-specific dynamics.

BACKGROUND: One of the seminal events since 2019 has been the outbreak of the SARS-CoV-2 pandemic. Countries have adopted various policies to deal with it, but they also differ in their socio-geographical characteristics and public health care facilities. Our study aimed to investigate differences between epidemiological parameters across countries. METHOD: The analysed data represents SARS-CoV-2 repository provided by the Johns Hopkins University. Separately for each country, we estimated recovery and mortality rates using the SIRD model applied to the first 30, 60, 150, and 300 days of the pandemic. Moreover, a mixture of normal distributions was fitted to the number of confirmed cases and deaths during the first 300 days. The estimates of peaks' means and variances were used to identify countries with outlying parameters. RESULTS: For 300 days Belgium, Cyprus, France, the Netherlands, Serbia, and the UK were classified as outliers by all three outlier detection methods. Yemen was classified as an outlier for each of the four considered timeframes, due to high mortality rates. During the first 300 days of the pandemic, the majority of countries underwent three peaks in the number of confirmed cases, except Australia and Kazakhstan with two peaks. CONCLUSIONS: Considering recovery and mortality rates we observed heterogeneity between countries. Liechtenstein was the "positive" outlier with low mortality rates and high recovery rates, at the opposite, Yemen represented a "negative" outlier with high mortality for all four considered periods and low recovery for 30 and 60 days.

Bioinformatic modelling of SARS-CoV-2 pandemic with a focus on country-specific dynamics

Background One of the seminal events since 2019 has been the outbreak of the SARS-CoV-2 pandemic. Countries have adopted various policies to deal with it, but they also differ in their socio-geographical characteristics and public health care facilities. Our study aimed to investigate differences between epidemiological parameters across countries. Method The analysed data represents SARS-CoV-2 repository provided by the Johns Hopkins University. Separately for each country, we estimated recovery and mortality rates using the SIRD model applied to the first 30, 60, 150, and 300 days of the pandemic. Moreover, a mixture of normal distributions was fitted to the number of confirmed cases and deaths during the first 300 days. The estimates of peaks' means and variances were used to identify countries with outlying parameters. Results For 300 days Belgium, Cyprus, France, the Netherlands, Serbia, and the UK were classified as outliers by all three outlier detection methods. Yemen was classified as an outlier for each of the four considered timeframes, due to high mortality rates. During the first 300 days of the pandemic, the majority of countries underwent three peaks in the number of confirmed cases, except Australia and Kazakhstan with two peaks. Conclusions Considering recovery and mortality rates we observed heterogeneity between countries. Liechtenstein was the "positive” outlier with low mortality rates and high recovery rates, at the opposite, Yemen represented a "negative” outlier with high mortality for all four considered periods and low recovery for 30 and 60 days.

Better safe than sorry-Whole-genome sequencing indicates that missense variants are significant in susceptibility to COVID-19.

Undoubtedly, genetic factors play an important role in susceptibility and resistance to COVID-19. In this study, we conducted the GWAS analysis. Out of 15,489,173 SNPs, we identified 18,191 significant SNPs for severe and 11,799 SNPs for resistant phenotype, showing that a great number of loci were significant in different COVID-19 representations. The majority of variants were synonymous (60.56% for severe, 58.46% for resistant phenotype) or located in introns (55.77% for severe, 59.83% for resistant phenotype). We identified the most significant SNPs for a severe outcome (in AJAP1 intron) and for COVID resistance (in FIG4 intron). We found no missense variants with a potential causal function on resistance to COVID-19; however, two missense variants were determined as significant a severe phenotype (in PM20D1 and LRP4 exons). None of the aforementioned SNPs and missense variants found in this study have been previously associated with COVID-19.

Gene Variants Related to Cardiovascular and Pulmonary Diseases May Correlate with Severe Outcome of COVID-19.

Background: Severe outcomes of COVID-19 account for up to 15% of all cases. The study aims to check if any gene variants related to cardiovascular (CVD) and pulmonary diseases (PD) are correlated with a severe outcome of COVID-19 in a Polish cohort of COVID-19 patients. Methods: In this study, a subset of 747 samples from unrelated individuals collected across Poland in 2020 and 2021 was used and whole-genome sequencing was performed. Results: The GWAS analysis of SNPs and short indels located in genes related to CVD identified one variant significant in COVID-19 severe outcome in the HADHA gene, while for the PD gene panel, we found two significant variants in the DRC1 gene. In this study, both potentially protective and risk variants were identified, of which variants in the HADHA gene deserve the most attention. Conclusions: This is the first study reporting the association between the HADHA and DRC1 genetic variants and COVID-19 severe outcome based on the cohort WGS analysis. Although all the identified variants are localised in introns, they may be correlated and therefore inherited along with other risk variants, potentially causative to severe outcome of COVID-19 but not discovered yet.

Beyond GWAS-Could Genetic Differentiation within the Allograft Rejection Pathway Shape Natural Immunity to COVID-19?

COVID-19 infections pose a serious global health concern so it is crucial to identify the biomarkers for the susceptibility to and resistance against this disease that could help in a rapid risk assessment and reliable decisions being made on patients' treatment and their potential hospitalisation. Several studies investigated the factors associated with severe COVID-19 outcomes that can be either environmental, population based, or genetic. It was demonstrated that the genetics of the host plays an important role in the various immune responses and, therefore, there are different clinical presentations of COVID-19 infection. In this study, we aimed to use variant descriptive statistics from GWAS (Genome-Wide Association Study) and variant genomic annotations to identify metabolic pathways that are associated with a severe COVID-19 infection as well as pathways related to resistance to COVID-19. For this purpose, we applied a custom-designed mixed linear model implemented into custom-written software. Our analysis of more than 12.5 million SNPs did not indicate any pathway that was significant for a severe COVID-19 infection. However, the Allograft rejection pathway (hsa05330) was significant (p = 0.01087) for resistance to the infection. The majority of the 27 SNP marking genes constituting the Allograft rejection pathway were located on chromosome 6 (19 SNPs) and the remainder were mapped to chromosomes 2, 3, 10, 12, 20, and X. This pathway comprises several immune system components crucial for the self versus non-self recognition, but also the components of antiviral immunity. Our study demonstrated that not only single variants are important for resistance to COVID-19, but also the cumulative impact of several SNPs within the same pathway matters.

History of Heart Failure in Patients Hospitalized Due to COVID-19: Relevant Factor of In-Hospital Complications and All-Cause Mortality up to Six Months.

BACKGROUND: Patients with heart failure (HF) are at high risk of unfavorable courses of COVID-19. The aim of this study was to evaluate characteristics and outcomes of COVID-19 patients with HF. METHODS: Data of patients hospitalized in a tertiary hospital in Poland between March 2020 and May 2021 with laboratory-confirmed COVID-19 were analyzed. The study population was divided into a HF group (patients with a history of HF) and a non-HF group. RESULTS: Out of 2184 patients (65 ± 13 years old, 50% male), 12% had a history of HF. Patients from the HF group were older, more often males, had more comorbidities, more often dyspnea, pulmonary and peripheral congestion, inflammation, and end-organ damage biomarkers. HF patients had longer and more complicated hospital stay, with more frequent acute HF development as compared with non-HF. They had significantly higher mortality assessed in hospital (35% vs. 12%) at three (53% vs. 22%) and six months (72% vs. 47%). Of 76 (4%) patients who developed acute HF, 71% died during hospitalization, 79% at three, and 87% at six months. CONCLUSIONS: The history of HF identifies patients with COVID-19 who are at high risk of in-hospital complications and mortality up to six months of follow-up.